GHK-Cu Is Next: Inside the FDA's February 2027 Peptide Review

The July 2026 PCAC meeting answered seven questions and quietly asked an eighth. Buried in the post-meeting outlook: the FDA expects another Pharmacy Compounding Advisory Committee consultation — this one involving GHK-Cu for noninjectable routes — before the end of February 2027. For the most widely used cosmetic peptide in the world, that is a genuinely big deal, and it tells us the July meeting was the start of a program, not a one-off.

Why GHK-Cu, and Why Noninjectable

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) occupies a different cultural lane than BPC-157 or TB-500. It is already ubiquitous in over-the-counter cosmetics — copper peptide serums are a mainstream skincare category — while injectable and higher-concentration compounded forms live in the same restricted territory as the July peptides. The signal that the FDA scoped the upcoming review to noninjectable routes suggests the agency wants to start with the lowest-risk question: topical and other non-parenteral compounded preparations, where systemic exposure concerns are smallest and the existing consumer footprint is largest.

What the July Meeting Teaches Us About February

• The panel's disposition is favorable but not automatic. Six approvals and one rejection in July showed a committee willing to override FDA staff — and also willing to say no when the evidence floor got too low (DSIP, 6–7). GHK-Cu arrives with a comparatively rich dermatological literature, decades of cosmetic-use history, and a route-of-administration scope designed to minimize safety objections. On paper, it walks into the friendliest setup of any peptide yet reviewed.
• Staff will still object to characterization gaps. The FDA's core critique in July was not indication-specific — it was that peptide substances lack standardized chemical definitions. Expect the same argument about copper-peptide complexes, chelation states, and what exactly a "GHK-Cu" monograph should specify.
• A recommendation still would not change the law. The July votes changed nothing legally, and a February GHK-Cu recommendation would not either. Rulemaking — 12 to 24 months when it happens — stands between any vote and any listing, with the 2022 glutathione recommendation still uncodified as the cautionary benchmark.

What This Means for Researchers and the Skincare Market

Nothing about OTC cosmetic copper peptides changes — that market is regulated as cosmetics and is unaffected by 503A questions. The February consultation is about compounded preparations: think prescription-strength topicals from licensed pharmacies. If GHK-Cu eventually lists, dermatology-adjacent telehealth would likely be the first commercial channel to move; Veritide tracks that provider landscape. For the peptide's underlying science — the wound-healing data, the skin-remodeling research, and its regulatory history — see our GHK-Cu profile, and for female-skew skincare protocols, FemPeptides covers the topical angle in depth.

The Bigger Picture

Sequence the events: April 2026, BPC-157 comes off Category 2. July 2026, seven peptides get PCAC votes and six pass. February 2027, GHK-Cu is queued. That is a cadence — a deliberate agency work program running peptides through the advisory process one batch at a time, under an HHS leadership publicly sympathetic to the category. Whether the rulemaking machinery downstream ever catches up with the advisory conveyor belt is the open question that will define peptide access for the rest of the decade. February is the next data point.